is a world leading CRO biotech company within protein production in Drosophila Schneider-2 (S2) cells. Our company has a proprietary and complete S2 recombinant protein technology base that we license to customers. We have in-depth practical experience with the Drosophila S2 expression technology for the production of recombinant proteins for preclinical development and for use in clinical trials. In 2017, two of our clients are conducting clinical Phase I/II trials on two different malaria parasite antigens, which are regulatory validated for manufacturing in our S2 technology platformExpreS2ion Biotechnologies
offers services related to vector development, cell line development, cloning, upstream development and optimization, and production of GLP material. ExpreS2ion Biotechnologies can facilitate GMP production scale-up in collaboration with our own preferred CMO partners or with the customer or their preferred CMO.